Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : TAVA Technologies (TAVA-NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Manzanillo who wrote (27959)	2/12/1999 9:30:00 AM
From: JDN	Respond to of 31646

To all: Folks, take a look at this press release. MAPICS is listed as a major competitor of TAVA. I own stock in MAPICS so follow it closely. Its stock is down from a high of 23 to 10 something. I bought in at 11 1/2. The company, like TAVA, continues to improve incredibly well. Sure would be nice if someday TAVA could have a PR like this. JDN Reply # of 109 Company Press Release MAPICS Directors Approve Share Repurchase Plan ATLANTA--(BUSINESS WIRE)--Feb. 10, 1999--MAPICS, Inc. (Nasdaq/NM:MAPX - news) today announced that its Board of Directors has authorized a plan to repurchase up to 1.8 million shares of the Company's common stock. The transactions may be made from time to time in the open market at prevailing market prices that the Company deems appropriate. MAPICS has approximately 23.5 million shares outstanding on a fully diluted basis. ''Given the strong operating results for our first quarter and the excellent fundamentals of our business, we believe that the purchase of shares affords MAPICS a highly attractive investment opportunity,'' said Richard C. Cook, president and chief executive officer. ''We are pleased that MAPICS' strong financial position, that includes approximately $30 million in cash, allows us to consider the repurchase of our shares. Although any transactions will depend on market conditions, we believe we can effectively execute against this authorization while maintaining our corporate goal of continuing to enhance our software solutions through product development, joint ventures and strategic acquisitions.'' MAPICS, Inc., headquartered in Atlanta, Georgia, is one of the world's leading providers of Enterprise Resource Planning (ERP) application software for manufacturers. Over 2,400 customers have selected MAPICS XA, its current product line. Through affiliate relationships, the Company provides solutions to customers in more than 70 countries. MAPICS, Inc. serves such customers as Bayer Corp.; General Electric Co., P.L.C.; Goodyear Tire & Rubber Co.; Honda Motor Co., Ltd.; IBM; Michelin Corp.; Volvo Corp.; Westinghouse Electric Corp. and York International. For more information, visit MAPICS' home page on the World Wide Web at www.mapics.com.

To: Manzanillo who wrote (27959)	2/12/1999 6:01:00 PM
From: Bill Wexler	Respond to of 31646

<<In other words, in your own mind you can be "correct" and broke>> No. I can be correct and patient. I am correct about the Zonagen fraud because the scientific evidence is irrefutable. Zonagen has never made any money and never will. It's sole purpose is to sell stock to gullible victims, that is why the stock is so volatile. Since I can't predict people's emotions...all I can do is to continue shorting until one event (in this case FDA rejection) collapses the stock. I've done this several times before with other biotech frauds. 100-200%++ squeezes are not uncommon in these stocks. I recently shorted Cyberguard starting at 7 and continued shorting while it climbed to 18 before it collapsed to zero. I can assure you I am far from broke. <<Bought in early January of 1997 at 9 3/8 sold in September at 35.>> <<No but I was smart, or lucky enough, to buy it in October for 2 7/8 and in November for 4 3/8.>> Amazing how so many people on these message boards have the uncanny ability to pick exact or near-exact tops and bottoms. You're lying. <<I think this will turn into a very profitable investment for me.>> It may. But I seriously doubt it. <<And that is why, if you shorted it at 15 as you say, you are losing 100% now that the stock is near 30.>> I extimate that my average shorting price for Zonagen is roughly 23. the stock closed today at around 28. It will eventually and inevitably trade below 5 a share.